Age-Related Macular Degeneration

Opthea Limited's (NASDAQ: OPT) OPT-302 data were presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference.  The data presented was a prespecified subgroup analysis of a Phase 2b dose-ranging study of intravitreal OPT-302 in...

The FDA has approved Genentech's, a unit of Roche Holdings AG (OTC: RHHBY), Vabysmo (faricimab-svoa) for wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME). Vabysmo targets and inhibits two disease pathways linked to several...

Adverum Biotechnologies Inc (NASDAQ: ADVM) plans to conduct a Phase 2 trial of ADVM-022 in wet AMD at 2 X 10^11 vg/eye dose and a new lower 6 X 10^10 vg/eye dose, with three new enhanced steroid prophylaxis regimens in wet age-related macular degeneration (wet AMD).  The...

Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY) Genentech to develop and commercialize retinal pigment epithelium (RPE) cell therapy. Genentech will assume responsibility...

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has announced six-month interim data from the Phase 1 trial of EYP-1901 in wet age-related macular degeneration (wet AMD). No reports of ocular SAEs or drug-related systemic SAEs were reported.  The data showed that 76% and 53% of...

Mizuho upgraded Unity Biotechnology Inc (NASDAQ: UBX) to Buy from Neutral with a price target of $7, up from $5 after Unity announced longer-term Phase 1 data for UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD). Analyst Salim Syed expects...

The FDA has signed off 4D Molecular Therapeutics' (NASDAQ: FDMT) Investigational New Drug Application (IND) for 4D-150 for wet age-related macular degeneration (wet AMD).  The active IND enables the initiation of a 4D-150 Phase 1/2 clinical trial, expected before year-end....

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD), for whom anti-VEGF therapy was no longer considered beneficial.  The data show strong...

Graybug Vision Inc (NASDAQ: GRAY) has provided a full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for wet age-related macular degeneration (wet AMD). GB-102 is Graybug's proprietary formulation of sunitinib malate injected twice a year intravitreally. Related Link:...

AbbVie Inc (NYSE: ABBV) and Regenxbio Inc (NASDAQ: RGNX) have partnered to develop and commercialize RGX-314, potential one-time gene therapy for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other chronic retinal diseases.  RGX-314 is...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) revealed new Phase 2 proof-of-concept trial data on Eylea (aflibercept) injection in patients with wet age-related macular degeneration (wet AMD). 43% of wet age-related macular degeneration patients dosed with an 8 mg dose of Eylea...

Unity Biotechnology Inc (NASDAQ: UBX) has announced positive data from its Phase 1 safety study of UBX1325 in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD) for whom anti-VEGF therapy was no longer considered beneficial.  UBX1325...

Iveric Bio Inc (NASDAQ: ISEE) has shared the new post-hoc analyses of GATHER1 and the progress of GATHER2 clinical trials evaluating Zimura (avacincaptad pegol) for geographic atrophy (G.A.) secondary to age-related macular degeneration (AMD). GATHER1 18 month post-hoc analyses show...

Stealth BioTherapeutics Corp (NASDAQ: MITO) shares soared in the premarket session in reaction to new data from a post hoc analysis of Phase 1 ReCLAIM study evaluating elamipretide in patients with noncentral geographic atrophy (GA) and high-risk drusen associated with dry age-...

Lineage Cell Therapeutics Inc (NYSE: LCTX) has updated interim results from its ongoing Phase 1/2a study of its lead product candidate, OpRegen, for dry age-related macular degeneration (AMD) with geographic atrophy (GA). OpRegen is an investigational cell therapy consisting of...